C12N 2795/14143
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2795/14143 (Viral genome or elements thereof as genetic vector) appears on 56 US grants and 70 published applications in this corpus.
Search patents in C12N- Granted patents
- 56
- Published applications
- 70
- Assignees
- 47
- Inventors
- 158
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 4 | 2 |
| 2003 | 4 | 4 |
| 2004 | 0 | 5 |
| 2005 | 3 | 2 |
| 2006 | 2 | 3 |
| 2007 | 1 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 1 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 4 |
| 2013 | 1 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 3 |
| 2016 | 0 | 3 |
| 2017 | 2 | 1 |
| 2018 | 1 | 6 |
| 2019 | 3 | 4 |
| 2020 | 3 | 2 |
| 2021 | 5 | 5 |
| 2022 | 4 | 3 |
| 2023 | 2 | 6 |
| 2024 | 3 | 1 |
| 2025 | 3 | 4 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials21 Apr 2026US 12,606,834 B2North Carolina State University
- Antibacterial phage, therapeutic composition, bactericidal agent, food, bacteria identification kit, therapeutic composition manufacturing method, bacteria elimination method, bacteria identification method, and animal therapeutic method23 Dec 2025US 12,502,413 B2Jichi Medical University
- M13 phage based gene therapy platform4 Nov 2025US 12,458,674 B2Massachusetts Institute of Technology
- Phagemid vector17 Jun 2025US 12,331,308 B2Imperial College Innovations Limited
- Evolution of BoNT peptidases13 Aug 2024US 12,060,553 B2Ipsen Biopharm Ltd.
- Engineered bacteriophage particle and method of gene therapy by using same8 Oct 2026US 2026/0308626 A1Academia Sinica
- Methods and compositions for targeted delivery of therapeutics11 Jun 2026US 2026/0158147 A1Manifold Biotechnologies, Inc.
- Reagents and methods for cell identification and characterization21 May 2026US 2026/0139244 A1
- Antibacterial phage, therapeutic composition, bactericidal agent, food, bacteria identification kit, therapeutic composition manufacturing method, bacteria elimination method, bacteria identification method, and animal therapeutic method30 Apr 2026US 2026/0115243 A1Jichi Medical University
- Engineered phage and kit for capturing sars-cov-2 and method for detecting sars-cov-2 virus by means of said phage or kit9 Apr 2026US 2026/0098861 A1Alma Mater Studiorum - Università di Bologna
Most cited
By later US patents
- Directed evolution of novel binding proteins2,450US 5,223,409 AProtein Engineering Corporation · 1993
- Viruses expressing chimeric binding proteins1,136US 5,403,484 AProtein Engineering Corporation · 1995
- Directed evolution of novel binding proteins1,057US 5,571,698 AProtein Engineering Corporation · 1996
- Methods and compositions for polypeptide engineering338US 6,586,182 B1Maxygen, Inc. · 2003
- Directed evolution of novel binding proteins286US 5,837,500 ADyax Corp. · 1998